Monograph of Amphotericin B

Introduction

otericin B is a polyene macrolide antifungal agent that has maintained a pivotal role in the treatment of severe systemic mycoses for over six decades. Its discovery in 1957 by S. S. and subsequent isolation from the soil bacterium Streptomyces nodosus established a new class of antifungal drugs characterized by potent activity against a broad spectrum of pathogenic fungi. Despite the advent of newer azoles and echinocandins, amphotericin B remains a cornerstone in the management of life‑threatening infections such as invasive candidiasis, aspergillosis, cryptococcosis, and histoplasmosis. The clinical relevance of this drug is underscored by its unique mechanism of action, which targets ergosterol in fungal cell membranes, thereby inducing pore formation and cell death. Understanding the pharmacological profile of amphotericin B is essential for optimizing therapeutic outcomes while mitigating its well‑documented adverse effects.

Learning objectives for this chapter include:

• Describe the historical development and classification of amphotericin B.
• Explain the molecular mechanism by which amphotericin B exerts antifungal activity.
• Summarize the pharmacokinetic properties and dosing strategies of both conventional and lipid‑based formulations.
• Identify the principal clinical indications, monitoring parameters, and potential drug interactions.
• Apply knowledge of amphotericin B pharmacology to clinical case scenarios involving complex antifungal therapy.

Fundamental Principles

Classification and Chemical Structure

Amphotericin B is classified as a polyene macrolide, a subclass of antibiotics derived from secondary metabolites of actinomycetes. Its molecular structure consists of a large lactone ring with conjugated double bonds that confer the characteristic yellow color. The amphathic nature of the molecule allows it to integrate into lipid bilayers, a property that is central to its antifungal activity. The drug is available in multiple formulations, including the deoxycholate salt (conventional) and lipid‑based preparations such as liposomal amphotericin B, amphotericin B lipid complex, and amphotericin B colloidal dispersion.

Pharmacodynamic Considerations

The primary pharmacodynamic target of amphotericin B is ergosterol, a sterol component unique to fungal cell membranes. Binding to ergosterol leads to the formation of transmembrane pores, causing leakage of intracellular ions and molecules, ultimately resulting in cellular hypoxia and death. The drug exhibits concentration‑dependent killing; however, due to its high protein binding and extensive tissue distribution, the relationship between serum concentrations and clinical efficacy is complex. The pharmacodynamic index most closely associated with efficacy is the area under the concentration–time curve (AUC) relative to the minimum inhibitory concentration (MIC). For amphotericin B, the AUC/MIC ratio is generally considered predictive of therapeutic success.

Key Terminology

Polyene macrolide – A class of antibiotics characterized by a macrolide lactone ring and multiple conjugated double bonds.
Ergosterol – A sterol found exclusively in fungal membranes, serving as a target for amphotericin B.
AUC – Area under the plasma concentration–time curve; a pharmacokinetic metric reflecting total drug exposure.
MIC – Minimum inhibitory concentration; the lowest drug concentration that inhibits visible growth of a microorganism.
Nephrotoxicity – Renal damage characterized by decreased glomerular filtration rate, electrolyte disturbances, and, in severe cases, acute kidney injury.
Infusion reactions – Adverse events such as fever, chills, hypotension, and bronchospasm that occur during or shortly after drug administration.

Detailed Explanation

Molecular Mechanism of Action

The interaction between amphotericin B and ergosterol is mediated through a two‑step process. Initially, amph B molecules embed themselves within the lipid bilayer, aligning parallel to the membrane plane. Subsequently, the drug clusters around ergosterol molecules, forming a complex that resembles a pore. The pore is sufficiently large to allow leakage of essential ions like potassium and magnesium, thereby disrupting cellular ionic gradients. This process is illustrated by the following representation of the rate of ion leakage (J) proportional to the number of pores (n) and the concentration of amphotericin B (C_AmB):

J = k × n × C_AmB

where k is a proportionality constant influenced by membrane composition and temperature. The resulting ionic imbalance precipitates cellular energy failure, cessation of protein synthesis, and ultimately lysis.

Pharmacokinetics

Amphotericin B demonstrates a highly complex pharmacokinetic profile. Following intravenous administration, the drug exhibits rapid distribution into extravascular tissues, resulting in a large apparent volume of distribution (V_d ≈ 6–8 L/kg). Oral bioavailability is negligible; therefore, the drug is not administered orally. The elimination half‑life (t_1/2) is typically 15–20 days, reflecting extensive tissue sequestration. The primary route of elimination is via the reticuloendothelial system, with minimal renal excretion of unchanged drug.

The concentration–time curve can be approximated by the exponential decay equation:

C(t) = C₀ × e^-k_elt

where C₀ is the initial concentration, k_el is the elimination rate constant, and t is time. The elimination rate constant can be calculated as:

k_el = ln(2) ÷ t_1/2

Given the long half‑life, steady state is rarely achieved, and dosing intervals are often determined by clinical response rather than pharmacokinetic equilibrium.

Formulation‑Related Differences

Lipid‑based formulations of amphotericin B were developed to reduce the incidence of nephrotoxicity and infusion reactions. In liposomal amphotericin B, the drug is encapsulated within a lipid bilayer vesicle, which alters its biodistribution and pharmacokinetics. The liposomal formulation achieves a higher concentration in fungal tissues while limiting renal exposure. Consequently, the therapeutic index is improved, allowing for higher dosing regimens (3–5 mg/kg/day) compared to conventional deoxycholate (0.3–1 mg/kg/day).

Toxicity Mechanisms

Nephrotoxicity is the dose‑limiting adverse effect of amphotericin B. The proposed mechanism involves direct tubular epithelial cell injury mediated by oxidative stress and depletion of intracellular glutathione. Additionally, the drug induces vasoconstriction of afferent arterioles, reducing renal perfusion. Hypomagnesemia, hypokalemia, and anemia are common laboratory abnormalities associated with amphotericin B therapy. Infusion reactions are mediated by cytokine release and complement activation, manifesting as fever, chills, and hypotension.

Clinical Significance

Indications

Amphotericin B is indicated for the treatment of a range of invasive fungal infections, including:

• Invasive candidiasis (especially in neutropenic patients or when resistance to azoles exists)
• Invasive aspergillosis (particularly in refractory cases or in patients with high fungal burden)
• Cryptococcal meningitis (initial induction therapy in HIV‑associated disease)
• Histoplasmosis, blastomycosis, and coccidioidomycosis (severe disseminated disease)
• Other rare infections such as mucormycosis and fusariosis when alternative agents are ineffective or contraindicated

In many clinical settings, amphotericin B remains the agent of choice for salvage therapy when newer antifungals fail or are contraindicated.

Dosing Strategies

Conventional deoxycholate formulation: 0.3–1 mg/kg/day intravenously, typically divided into 1–2 daily infusions. Lipid formulations: 3–5 mg/kg/day, often administered once daily. The choice of formulation is guided by patient factors such as renal function, severity of disease, and risk of infusion reactions.

Monitoring parameters:

• Serum creatinine and estimated glomerular filtration rate (eGFR) every 2–3 days during initial therapy.
• Serum electrolytes (magnesium, potassium) twice weekly.
• Complete blood count to detect anemia or leukopenia.
• Assessment for infusion reactions during the first infusion and subsequent administrations.

Drug Interactions

Amphotericin B may potentiate the nephrotoxic effects of other agents such as aminoglycosides, vancomycin, and nonsteroidal anti‑inflammatory drugs. Concomitant use of drugs that inhibit renal perfusion (e.g., NSAIDs, ACE inhibitors) should be approached with caution. Additionally, the drug’s high protein binding may displace other highly bound medications, potentially leading to elevated free drug concentrations.

Clinical Outcomes

When administered appropriately, amphotericin B achieves high cure rates in life‑threatening fungal infections. However, the therapeutic benefit must be weighed against the risk of toxicity. Recent data suggest that lipid formulations reduce the incidence of nephrotoxicity by approximately 50% compared with deoxycholate, while maintaining comparable efficacy. Nevertheless, cost considerations may limit the availability of lipid preparations in resource‑constrained settings.

Clinical Applications/Examples

Case 1: Neutropenic Patient with Invasive Candidemia

A 62‑year‑old male with acute myeloid leukemia develops persistent fever and positive blood cultures for Candida glabrata despite fluconazole therapy. Due to the high MIC of the isolate, amphotericin B is initiated at 1 mg/kg/day of the liposomal formulation. Renal function is monitored; serum creatinine remains stable, and no significant electrolyte disturbances occur. After 14 days of therapy, blood cultures become negative, and the patient is transitioned to oral fluconazole for maintenance therapy.

Case 2: Refractory Invasive Aspergillosis in an Immunosuppressed Transplant Recipient

A 45‑year‑old woman receiving tacrolimus for kidney transplantation presents with pulmonary infiltrates and positive galactomannan antigen. Voriconazole therapy fails to improve symptoms. Amphotericin B deoxycholate is started at 0.5 mg/kg/day, with close monitoring of tacrolimus trough levels. Tacrolimus concentrations rise, necessitating dose reduction. Over the next 8 weeks, radiographic improvement is noted, and the patient is discharged on a reduced amphotericin B regimen for continuation therapy.

Case 3: HIV‑Associated Cryptococcal Meningitis

A 34‑year‑old man with newly diagnosed HIV presents with headache, fever, and neck stiffness. Cerebrospinal fluid analysis confirms cryptococcal infection. Induction therapy with amphotericin B deoxycholate (0.3 mg/kg/day) and flucytosine (100 mg/kg/day) is initiated. Serial lumbar punctures are performed to monitor opening pressure. Despite early amphotericin B toxicity (diarrhea, nausea), the patient’s clinical status improves, and after 2 weeks, the amphotericin B is discontinued in favor of oral fluconazole for consolidation.

Summary / Key Points

• Amphotericin B is a potent polyene macrolide with a unique mechanism targeting ergosterol in fungal cell membranes, leading to pore formation and cell death.
• Its pharmacokinetic profile is characterized by extensive tissue distribution, prolonged half‑life, and minimal renal excretion of unchanged drug.
• Conventional deoxycholate formulation is limited by nephrotoxicity and infusion reactions; lipid‑based formulations mitigate these adverse effects while preserving efficacy.

Therapeutic monitoring includes renal function, electrolytes, and vigilant assessment for infusion reactions, particularly during the first infusion.

• Amphotericin B remains essential for treating severe invasive fungal infections, especially when newer agents fail or resistance is suspected.

Clinical pearls:

• Initiate lipid formulations in patients with pre‑existing renal impairment or high risk of nephrotoxicity.
• Administer the first infusion slowly over at least 4 hours, with pre‑medication (e.g., acetaminophen, diphenhydramine) to reduce infusion reactions.
• Monitor serum magnesium and potassium twice weekly; replace electrolytes promptly to prevent arrhythmias and neuromuscular complications.
• Adjust concomitant nephrotoxic drugs (e.g., aminoglycosides) to minimize cumulative renal risk.
• Consider therapeutic drug monitoring of amphotericin B only in specialized settings, as evidence for routine monitoring remains limited.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.